EDITORIAL - A vaccine gone awry
(The Philippine Star) - December 3, 2017 - 4:00pm

Congress and the Department of Justice have set investigations, but both will have to rely on information from health experts as a review and more research are conducted on the safety and efficacy of a vaccine against dengue.

Pharmaceutical giant Sanofi Pasteur launched Dengvaxia as a vaccine against the mosquito-borne viral disease that infects an average of 390 million people worldwide every year. People in warm countries including the Philippines face the highest risk. The country was among the first to use Dengvaxia on children at least nine years old.

Late last month, however, Sanofi itself, after analyzing long-term clinical trial data, announced that Dengvaxia worked only on those who have already suffered dengue. Those without a history of the disease face risks including greater vulnerability to infection. A statement from Sanofi said the long-term trial results highlighted “the complex nature” of dengue infection as it proposed a “label update” on the use of the vaccine.

Former health secretary Janette Garin, under whose watch P3.5 billion worth of Dengvaxia was procured by the government, said this was done in accordance with World Health Organization guidelines and with the vaccine cleared by the country’s Food and Drug Administration. Since last year, 733,713 children have been vaccinated by the Department of Health in Metro Manila, Central Luzon and Calabarzon. The DOH says about 70,000 of the children have no history of dengue and are therefore at risk.

Whether ongoing investigations will hold certain former officials liable for the mess, attention must be focused on any adverse effects that might be suffered by children with no history of dengue who have received the vaccine. Health professionals must work with school authorities and local government personnel for close monitoring of potential complications. With the risk identified, every effort must be made to protect the children from the consequences.

Philstar
Facebook
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

SIGN IN
or sign in with
Read and share the latest news
whenever and wherever you are.
Top Stories
Features the most relevant stories,
exclusive content, analyses and special reports.
As It Happens
Get bite-sized highlights and up-to-date
information as the news breaks.
Latest
View the most recent
stories of the day.
Log-in
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Quisque justo est, auctor vel ullamcorper.
Log-in
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Quisque justo est, auctor vel ullamcorper.
How to follow As It Happens stories
STEP 1
Click the story in the As it Happens section.
How to follow As It Happens stories
STEP 2
Click "Follow Story" for updates on the news.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam eu metus vitae felis tincidunt finibus ut id sapien. Integer volutpat dui eu malesuada dignissim. Sed varius justo nulla, fringilla convallis sem porta sed.
How to follow Author
STEP 1
Click on the author's name in the article.
How to follow Author
STEP 2
Once you click on the author's name, you will be
brought to the Authors page. Click "Follow Author"
to stay updated on the author's works
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam eu metus vitae felis tincidunt finibus ut id sapien. Integer volutpat dui eu malesuada dignissim. Sed varius justo nulla, fringilla convallis sem porta sed.
How to follow Tags
STEP 1
Click on a tag in the article.
How to follow Tags
STEP 2
When you click on a tag, it will take you to the
dedicated tag page where you'll see the article
viewed, along with other stories with that tag.

Click the "follow tag" button to stay updated on
the topic.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam eu metus vitae felis tincidunt finibus ut id sapien. Integer volutpat dui eu malesuada dignissim. Sed varius justo nulla, fringilla convallis sem porta sed.